C/ Isabel Sandy, 2 - AD700 Escaldes-Engordany

FAQS Blog +376 821 920 Contact

Blog

Non-invasive prenatal screening using maternal blood

22/04/2026

Non-invasive prenatal screening using maternal blood

VeriRef® and VeriRef Gold® Non-invasive genomic prenatal test

What is non-invasive prenatal screening?

NIPS is a laboratory test that estimates, from fetal DNA in maternal blood, the risk of trisomy involving chromosomes 13, 18, 21, X and Y in the fetus.

What are its advantages?

Results within approximately 12 working days.
In the event of a high-risk result, we will offer confirmation by CGH array completely free of charge, using a fetal sample (amniotic fluid or chorionic villi).
If no result is obtained due to a low presence of fetal DNA in maternal blood (< 1% of cases), no cost will be charged.
Determines the baby’s sex.
Allows the detection of aneuploidies (variation in copy number) of the X and Y chromosomes.
Sample collection is carried out from Monday to Thursday.
It can be performed from the 10th week of pregnancy.
It can be performed in cases of egg donation and twin pregnancies; in this case, only aneuploidies of chromosomes 13, 18 and 21 are reported.

Specificity	Above 99%. Much higher than first-trimester combined screening tests.
Sensitivity	Over 99% for the detection of Down syndrome, much higher than first-trimester combined screening tests.
Robustness	Greater robustness, as it does not depend on cell culture and can be performed across a wide range of gestational weeks.
Safety	As it is performed using maternal blood, there is no risk to the fetus.

Please note:

The test is performed using 10 ml of peripheral blood.
As this is a genetic test, it is essential to complete the Genetic Counselling Document.

Cookie settings

All information accessible through this WEB service belongs to the natural persons to whom each piece of information accessed refers.

IMPORTANT!!! In accordance with Article 19 of Law 15/2003 of 18 December, the Qualified Law on Personal Data Protection, data relating to the health of natural persons are considered sensitive data and may therefore only be processed or communicated with the express consent of the data subject.

Accordingly, each user is responsible for making correct and professional use of the data obtained through this information channel. The user is responsible for ensuring the confidentiality of the personal data being processed and for preventing their disclosure or unauthorised access. The User Administrator designated by Bio-Centre must assign each user a Username, which is personal and non-transferable. Each user shall be responsible for the privacy of their access password, making as many password changes as they deem necessary to ensure such privacy.

Neither BIO-CENTRE, as the system operator, nor DAS, S.L., as the system developer and implementer, shall be held responsible for any misuse of the information resulting from incorrect use of the system by the user.

BIO-CENTRE is responsible for the proper management of users by appointing a User Administrator who correctly assigns permissions to each user who must have access to the system. BIO-CENTRE is also responsible for the proper management of the system, ensuring maximum security and privacy in the communication lines through which this service is accessible.

BIO-CENTRE, as the system operator, shall not be held responsible for any misuse of information obtained as a result of security breaches in the communication lines and following illegal decryption of the information.

DAS, S.L., as the system developer and implementer, provides a user management framework in accordance with current legal requirements; it offers an unlimited record of all consultation and modification activities relating to the data accessed through this service, which is stored within the data structure of the SilverlabNet system, and provides encryption of all communications (configurable).

DAS, S.L., as the system developer and implementer, shall not be held responsible for any misuse of information obtained as a result of security breaches in the communication lines in cases where the information is transmitted unencrypted.

In the event of detecting any abnormal operation of the system, the user must notify BIO-CENTRE, which will report it to the Incident Assistance Service (SAI), in order to assess its criticality and proceed with the appropriate corrective actions.